| FBCIX | TZINX | FBCIX / TZINX | |
| Total Expense Ratio | 0.36 | 0.96 | 38% |
| Annual Report Gross Expense Ratio | 0.36 | 1.01 | 36% |
| Fund Existence | 5 years | 20 years | - |
| Gain YTD | 19.663 | 24.223 | 81% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 250 | 100000 | 0% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 121B | 312M | 38,782% |
| Annual Yield % from dividends | 3.12 | 3.70 | 84% |
| Returns for 1 year | 14.77 | 20.27 | 73% |
| Returns for 3 years | 40.12 | 45.60 | 88% |
| Returns for 5 years | 54.24 | 24.96 | 217% |
| Returns for 10 years | N/A | 28.36 | - |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| PAGRX | 135.15 | 1.54 | +1.15% |
| Permanent Portfolio Aggressive Growth I | |||
| FBTDX | 166.82 | 1.60 | +0.97% |
| Franklin Biotechnology Discovery C | |||
| MGGPX | 35.69 | 0.25 | +0.71% |
| Morgan Stanley Inst Global Opp A | |||
| VITNX | 113.75 | 0.78 | +0.69% |
| Vanguard Instl Ttl Stk Mkt Idx I | |||
| BPLSX | 15.29 | 0.09 | +0.59% |
| Boston Partners Long/Short Equity Instl | |||